| Característica |
Objectiu de la convocatòria
The aims of the call are:
to support translational research projects that combine innovative approaches in the field
of nanomedicine
to encourage and enable transnational collaboration between academic research (public
and private partners and clinical/public health research or R&D activities from industrial enterprises (all size)
|
Característiques principals
Project proposals will address multidisciplinary and translational research. The applications must cover
at least one of the following nanomedicine areas that are of equal relevance for this call:
Regenerative medicine
Diagnostics
Nanotherapy
For a better understanding of the objectives and a more efficient evaluation, applicants are asked to
specify in which of the two categories described below the project falls, according to its Technology
Readiness Levels (TRL), i.e. its degree of innovation and expected time to market:
Innovation applied research projects: Proof of concept projects for innovative applications
with analytical/experimental research and/or implementation and integration of components
and test in laboratory and/or animal models. Safety and nanotoxicity should be taken into
account when relevant. The viability of a path that may lead the experimental and/or analytical
results (for TRL 3) and/or demonstrators (for TRL 4) to a future application at medium/long
term shall also be demonstrated.
Projects with high potential of applicability at short/medium term: Projects closer to the
market for the validation of demonstrators and prototypes in a realistic laboratory (for TRL 5)
and/or relevant simulated operational field environment (for TRL-6). The viability of a path
that may lead the validated systems and results to real products shall be demonstrated.
Industrial engagement is crucial in this type of projects. Medical regulatory aspects have to be
properly considered.
|
Lloc de presentació
IMIM and PSMAR staff who need more information should contact::
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
Marta López: mlopez4@imim.es Ext.: 1576
|
Convocatòria (URL)
https://era4health.eu/nanotecmec-2024/
Submission Tool:
https://ptoutline.eu/app/era4healthnano
|
Informació addicional
The call follows a two-stage procedure.
|
Requisits
Joint research proposals may be submitted by applicants belonging to one of the following categories (according to national/regional regulations; certain categories may not be eligible for funding by a specific funding organisation, please see Annex I of the call text):
Academia – research teams working in universities, other higher education institutions or research institutes.
Clinical/public health sector – research teams working in hospitals/public health and/or other health care settings and health organisations.
Enterprises – private companies of all sizes.
Operational stakeholders – e.g. patient advocacy organisations, municipalities and local governments, local/national NGO’s. In line with the concept of RRI, operational stakeholders should be in a position to provide useful knowledge to the consortium, ensure the consortium’s research is useful and translatable to their (or other) organizational contexts, and/or influence decision making or create change within their organisations. Operational stakeholders should be engaged in the research process from conception of the study to dissemination.
Only transnational projects will be funded. The following conditions apply to the composition of consortia:
Minimum of three eligible and a maximum of five eligible partners from at least three different countries participating in the call (see list above).
The maximum number of eligible partners can be increased up to six or seven (see table below) if they include one or two partners, respectively, from the following participating countries: Latvia, Lithuania, Slovakia, Türkiye.
No more than two eligible partners from the same country participating in the call will be accepted within one consortium.
Maximum of two collaborators per consortium. Collaborators are self-funded partners: i.e. partners that do not request funds in this Joint Transnational Call provided by one of the participating funding organisations (i.e. partners from non-funding countries or partners which are not fundable according to national/regional regulations of the participating funding organisations).
Please consult the call text for detailed eligibility requirements.
|
Dotació
Maximum funding from ISCIII per awarded Spanish project:
If a Spanish Partner requesting funding to the ISCIII IS NOT the Coordinator of the transnational project:
220.000€ (overheads included), if there is only one Spanish Partner requesting funding to the ISCIII in the proposal.
275.000€ (overheads included), if there are two Spanish Partners requesting funding to the ISCIII in the proposal.
If a Spanish Partner requesting funding to the ISCIII IS the Coordinator of the transnational project:
320.000€ (overheads included), if there is only one Spanish Partner in the proposal, acting as a coordinator.
400.000€ (overheads included), if there is one Spanish Partner in addition to the Spanish Coordinator in the
proposal, both requesting funding to the ISCIII.
|
Durada
From 24 to 36 months.
|
AVÍS IMPORTANT
The call is made at European level but each partner of the consortium is funded by its national funding agency and must follow its national funding rules (please see the Call text).
Due to the complexity of the call, if you are interested in submitting an application we strongly recommend that you contact the Research Grants and Contracts Office well in advance of the deadline.
|